AGP Executive Report
Last update: 20 hours agoPediatric Long COVID Burden: A prospective PECOS study found 20 symptoms more common in lab-confirmed SARS-CoV-2–infected children and teens, with about two-thirds reporting at least one post-infection symptom at 12 months. Cancer Care Advances: At ASCO 2026, a radiation implant with “seeds” after brain metastasis surgery showed better outcomes than external beam radiation, while SENOMAC data suggest omitting axillary lymph node dissection can be non-inferior with fewer arm complications. Urothelial Carcinoma Survival: Updated EV-302/KEYNOTE-A39 results show enfortumab vedotin plus pembrolizumab continues to improve overall survival vs platinum chemo in first-line locally advanced/metastatic disease. Quality of Life in Neuroendocrine Tumors: 177Lu-edotreotide improved health-related quality of life versus everolimus in GEP-NETs. Diagnostics Coverage Gap: ASCO 2026 coverage gaps persist for molecular testing in children’s cancers, especially bone cancers, with Medicare denials still common. Health System Watch: PacificSource plans layoffs in Oregon as it exits parts of ACA markets, leaving tens of thousands needing new coverage.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
